


(19)  **Europäisches Patentamt**
European Patent Office
Office européen des brevets



(11) **EP 1 195 165 A1**

(12) **EUROPEAN PATENT APPLICATION**
published in accordance with Art. 158(3) EPC

(43) Date of publication: **10.04.2002 Bulletin 2002/15**
(51) Int Cl.7: **A61K 45/00, A61K 31/661**
(21) Application number: **00944365.6**
(86) International application number: **PCT/JP00/04583**
(22) Date of filing: **10.07.2000**
(87) International publication number: **WO 01/03739 (18.01.2001 Gazette 2001/03)**

<p>(84) Designated Contracting States: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE</p> <p>(30) Priority: 12.07.1999 JP 19689299</p> <p>(71) Applicant: ONO PHARMACEUTICAL CO., LTD. Osaka-shi, Osaka 541-8526 (JP)</p>	<p>(72) Inventors:</p> <ul style="list-style-type: none"> • KISHIKAWA, Katsuya, ONO Pharmaceutical Co., Ltd. Mishima-gun, Osaka 618-858 (JP) • MATSUMOTO, Shigeru, ONO Pharmaceutical Co., Ltd. Mishima-gun, Osaka 618-8585 (JP) <p>(74) Representative: Henkel, Feiler, Hänzeler Möhlstrasse 37 81675 München (DE)</p>
---	--

(54) **FIBROSIS INHIBITORS CONTAINING AS THE ACTIVE INGREDIENT
SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST OR SPHINGOSINE-1-PHOSPHATE**


(57) An anti fibrotic agent, comprising a sphingosine 1-phosphate (S1P) receptor agonist or sphingosine 1-phosphate (S1P) as an active ingredient. Since an S1P receptor agonist, particularly S1P, has activity of inhibiting fibrosis in various organs, it is useful in preventing and/or treating diseases caused by fibrosis in organs, such as pulmonary fibrosis, interstitial pneumonia, chronic hepatitis, hepatic cirrhosis, chronic renal failure, renal glomerulosclerosis, etc.

EP 1 195 165 A1

Description

TECHNICAL FIELD

[0001] The present invention relates to an anti fibrotic agent comprising a sphingosine 1-phosphate receptor agonist as an active ingredient. Particularly, the present invention relates to an anti fibrotic agent, comprising, as an active ingredient, sphingosine 1-phosphate represented by the following formula:



BACKGROUND OF THE INVENTION

[0002] Sphingolipid as one of the cell membrane-constituting lipid-soluble components contains two kinds, sphingomyelin and glycolipid. They are converted into ceramides enzymatically via sphingomyelinase and endoglycanase, and then metabolized into sphingosine by a ceramidase. Furthermore, the sphingosine is then converted into sphingosine 1-phosphate (hereinafter referred to as "S1P") by a sphingosine kinase.

[0003] Studies on such intracellular metabolism of sphingolipid have been carried out since 1960's, but until now, S1P has been recognized only as one of the intermediate metabolic products in the sphingolipid metabolism. However, S1P is focused because its physiological activities are being revealed recently.

[0004] For example, the followings are known as the activities possessed by S1P.

(1) Cell growth accelerating activity on Swiss 3T3 fibroblast by calcium mobilization (*J. Cell. Biol.*, 114, 155-167 (1991)).

(2) Control of cellular chemotactic activity of a cancer cell line (*Proc. Natl. Acad. Sci. USA*, 89, 9686-9690 (1992)).

(3) Inhibition of PDGF (platelet-derived growth factor)-dependent cellular mobilization of smooth muscle cells (*J. Cell. Biol.*, 130, 193-206 (1995)).

(4) Function as a second messenger. For example, S1P acts as an intracellular second messenger in a cell growth stimulation by PDGF etc. (*Nature*, 365, 557-560 (1993)) and it also acts as an intracellular second messenger in the intracellular calcium mobilization via a high affinity IgE receptor of a rat mast cell, RBL-2H3 cell (*Nature*, 380, 634-636 (1996)).

(5) Inhibition of apoptosis by ceramide etc. (*Nature*, 381, 800-803 (1996)). Opposite activity is suggested a possibility that it acts as a signal molecule of apoptosis induction of leukocyte (*FEBS Lett.*, 355, 267 (1995)), which may have a different mechanism.

(6) Since S1P has been reported to act as an extracellular moiety via a cell surface receptor, its role as an inter-cellular messenger is also focused. In addition, with the recent advance in the identification and cloning of S1P receptors, Edg-1 (endothelial cell differentiation gene-1), Edg-3, AGR16/H218 (Edg-5), Edg-6 and Edg-8 have been reported as specific S1P receptors (*Science*, 279, 1552-1555 (1998), *Biochem. J.*, 330, 605-609 (1998), *FEBS Lett.*, 417, 279-282 (1997), *Blood*, 95, 2624-2629 (2000), *J. Biol. Chem.*, 275, 14281-14286 (2000)).

[0005] The specification of WO 93/19760 (JP-T-8-500816) describes a method for using S1P in the inhibition of active chemotactic property of tumor cells, inhibition of invasion of tumor cells, inhibition of inflammation by the active property of neutrophils, inhibition of metastasis of malignant tumor cells etc.

[0006] The specification is provided that a method for inhibiting inflammation. However, it merely describes that since the inflammation steps are dependent on the mobilization of neutrophils, S1P which inhibits the mobilization is expected to be useful in inhibiting the inflammation steps.

[0007] The specification of US Patent 5,712,262 describes that S1P suppressed programmed cell death.

[0008] While various physiological activities of S1P are being revealed as described above, its activities regarding fibrosis are also studied. For example, as shown in the above item (1), it has been confirmed that S1P accelerates cell growth of Swiss 3T3 fibroblast and acts as an intracellular signal molecule which mobilizes calcium from its intracellular store, and it has been confirmed thereafter that sphingosine derivatives have activities similar to S1P (*J. Biol. Chem.*, 273(36), 23585-23589 (1998)). Thus, it has been reported that S1P and its related substances are concerned in the growth of fibroblast.

DISCLOSURE OF THE INVENTION

[0009] As a result of extensive studies on the physiological activities possessed by S1P, the present inventors have found unexpectedly that it has activity of suppressing fibrosis of organs and thereby accomplished the present invention.

5 This is a result which cannot be expected at all in view of the prior art but confirmed for the first time by the inventors based on experiments.

[0010] In addition, it is known that S1P receptors are expressed in each organ. For example, it is known that S1P receptors Edg-1, Edg-3, Edg-5 and Edg-6 are expressed in the lungs, and S1P receptors Edg-1, Edg-3 and Edg-5 are expressed in the liver and kidney (*Genomics*, 53, 164-169 (1998), *B. B. A.*, 1484, 107-116(2000)).

10 [0011] Thus, based on these facts, it was also found that inhibition of fibrosis in various organs by S1P receptor agonists can be fully predicted.

[0012] The present invention relates to an anti fibrotic agent for various organs, comprising an S1P receptor agonist as an active ingredient. Particularly, the present invention relates to an anti fibrotic agent for various organs, comprising S1 P as an active ingredient.

15 [0013] The S1P used in the present invention is a known substance (CAS registration number: 26993-30-6) and is commercially available.

[0014] Regarding the S1P receptor of the present invention, all of the receptors so far known (e.g., Edg-1, Edg-3, AGR16/H218 (Edg-5), Edg-6 and Edg-8) and which will be identified in the future are included.

20 [0015] As the S1P receptor agonist of the present invention, all of the S1P receptor agonist compounds so far known and compounds which will be found in the future are included.

INDUSTRIAL APPLICABILITY

25 [0016] It has been known that S1 P is concerned in the growth of fibroblast. In general, it is considered that growth of fibroblast leads to the acceleration of fibrosis in organs. However, the inventors have found a fact that S1P inhibits fibrosis, which is a completely opposite result of the commonly known information.

[0017] Accordingly, since S1P has activity of inhibiting fibrosis in various organs, it is useful in preventing and/or treating pulmonary fibrosis, interstitial pneumonia, chronic hepatitis, hepatic cirrhosis, chronic renal failure, renal glomerulosclerosis and the like.

30 [0018] Also, based on the fact that S1P inhibits fibrosis, it can be fully predicted that an S1P receptor agonist will inhibit fibrosis in organs.

[0019] Accordingly, since the S1P receptor agonist has activity of inhibiting fibrosis in various organs, it is considered to be useful in preventing and/or treating pulmonary fibrosis, interstitial pneumonia, chronic hepatitis, hepatic cirrhosis, chronic renal failure, renal glomerulosclerosis and the like.

Toxicity:

35 [0020] Since toxicity of the S1P used in the present invention is low, it can be judged that it is sufficiently safe in using it as a medicament.

Application for Pharmaceuticals

40 [0021] The S1P receptor agonist or S1P of the present invention may normally be administered systemically or topically, usually by oral or parenteral administration.

45 [0022] The doses to be administered are determined depending upon, for example, age, body weight, symptom, the desired therapeutic effect, the route of administration, and the duration of the treatment. In the human adult, the doses per person are generally from 1 mg to 1000 mg, by oral administration, up to several times per day, and from 0.1 mg to 100 mg, by parenteral administration (preferably intravenous administration), up to several times per day, or continuous administration from 1 to 24 hours per day from vein.

50 [0023] As mentioned above, the doses to be used depend upon various conditions. Therefore, there are cases in which doses lower than or greater than the ranges specified above may be used.

[0024] The compounds of the present invention may be administered in the form of, for example, solid forms for oral administration, liquid forms for oral administration, injections, liniments or suppositories for parenteral administration.

55 [0025] Solid forms for oral administration include compressed tablets, pills, capsules, dispersible powders, and granules etc. Capsules include hard capsules and soft capsules.

[0026] In such solid forms, one or more of the active compound(s) may be admixed with vehicles (such as lactose, mannitol, glucose, microcrystalline cellulose, starch, etc.), binders (such as hydroxypropyl cellulose, polyvinylpyrrolidone or magnesium metasilicate aluminate, etc.), disintegrants (such as cellulose calcium glycolate, etc.), lubricants

(such as magnesium stearate, *etc.*), stabilizing agents, and solution adjuvants (such as glutamic acid or aspartic acid, *etc.*) and prepared according to methods well known in normal pharmaceutical practice. The solid forms may, if desired, be coated with coating agents (such as sugar, gelatin, hydroxypropyl cellulose or hydroxypropylmethyl cellulose phthalate, *etc.*), or be coated with two or more films. And further, coating may include containment within capsules of absorbable materials such as gelatin.

[0027] Liquid forms for oral administration include pharmaceutically acceptable solutions, suspensions and emulsions, syrups and elixirs, *etc.* In such forms, one or more of the active compound(s) may be dissolved, suspended or emulsified into diluent(s) commonly used in the art (such as purified water, ethanol or a mixture thereof, *etc.*). Besides such liquid forms may also comprise some additives, such as wetting agents, suspending agents, emulsifying agents, sweetening agents, flavoring agents, aroma, preservative or buffering agent, *etc.*

[0028] Injections for parenteral administration include sterile aqueous, suspensions, emulsions and solid forms which are dissolved or suspended into solvent(s) for injection immediately before use. In injections, one or more of the active compound(s) may be dissolved, suspended or emulsified into solvent(s). The solvents may include distilled water for injection, physiological salt solution, vegetable oil, propylene glycol, polyethylene glycol, alcohol, e.g. ethanol, or a mixture thereof, *etc.* Injections may comprise some additives, such as stabilizing agents, solution adjuvants (such as glutamic acid, aspartic acid or POLYSORBATE80 (registered trade mark), *etc.*), suspending agents, emulsifying agents, soothing agent, buffering agents, preservative, *etc.* They may be sterilized at a final step, or may be prepared and compensated according to sterile methods. They may also be manufactured in the form of sterile solid forms (such as freeze-dried products) which may be dissolved in sterile water or some other sterile diluent(s) for injection immediately before use.

[0029] Other forms for parenteral administration include liquids for external use, ointments and endermic liniments, inhalations, sprays, suppositories and pessaries for vaginal administration which comprise one or more of the active compound(s) and may be prepared by methods known per se.

[0030] Sprays may comprise additional substances other than diluents, such as stabilizing agents (such as sodium sulfate), isotonic buffers (such as sodium chloride, sodium citrate or citric acid). For preparation of such sprays, for example, the method described in the United States Patent No. 2,868,691 or 3,095,355 may be used.

BEST MODE FOR CARRYING OUT THE INVENTION

[0031] The activity of S1P to inhibit fibrosis of organs was confirmed by the following test.

Test Method:

Production of bleomycin-induced lung injury model animal:

[0032] Using each of ICR male mice and under pentobarbital (60 mg/kg, i.v.) anesthesia, the cervical region was shaved and the skin was incised for about 4 mm from under the larynx region along the median line. Next, the muscle layer covering upper trachea was peeled off to expose the trachea. Using a micro-syringe, physiological saline or bleomycin hydrochloride (0.03 mg/animal, manufactured by Nippon Kayaku) was administered tracheally (50 μ l/animal) from the tracheal smooth muscle region between cricoid cartilage. After the administration, the incised region was closed and antibiotics were administered into the thigh intramuscularly in order to prevent infection. S1P (10 mg/5 ml/kg, 0.5% aqueous solution of carboxymethylcellulose sodium (CMC-Na)-physiological saline, manufactured by Matreya) was intraperitoneally administered once a day for 14 days after the bleomycin induction. Tests on the physiological saline group (normal group) and bleomycin-induced groups (control group and S1P-administered group) were each carried out using 10 animals. Fifteen days after the induction, each animal was sacrificed by exsanguination under pentobarbital (60 mg/kg, i.v.) anesthesia, and a lung (1 mg) tissue was excised.

[0033] Measurement of the lung fibrosis was carried out based on the lung tissue hydroxyproline content as shown below.

[0034] The excised lung parenchyma was cut into fine strips of about 2 to 3 mm, transferred into a heat-resistant screw test tube using distilled water (0.4 ml) and then freeze-dried. After overnight freeze-drying, 6 N hydrochloric acid (2.5 ml) was added thereto to carry out hydrolysis at 110°C for 24 hours. After the hydrolysis, this sample was neutralized with 6 N sodium hydroxide aqueous solution (2.5 ml). Thereafter, this was centrifuged (1,000 \times g, 5 minutes) and the resulting supernatant (25 μ l) was used in the determination of hydroxyproline.

[0035] The hydrolyzed supernatant (25 μ l) was mixed with borate-alanine buffer (2.475 ml) separately prepared, and potassium chloride (solid) was added thereto until it was saturated. To the mixture, 0.2 M chloramine T (0.6 ml) was added, and incubated at room temperature for 40 minutes for oxidation, and the oxidation was terminated with 3.6 M sodium thiosulfate (2 ml). Toluene (3 ml) was added thereto, followed by sufficiently mixing and heating for 30 minutes in a boiling water bath. Next, the resulting mixture was cooled with tap water, followed by centrifugation (1,000 \times g, 5

EP 1 195 165 A1

minutes) to separate the toluene layer (1.5 ml). Ehrlich's reagent (0.6 ml) was added thereto to carry out the color development at room temperature for 30 to 40 minutes. The absorbance of each sample was immediately measured at 560 nm, and the amount of hydroxyproline in the sample was calculated from a calibration curve. The results are shown in Table 1.

Table 1

	Bleomycin-induced S1P administered group [S]	Bleomycin-induced S1P unadministered group [C]	Physiological saline- induced S1P unadministered group [B]
Hydroxyproline content (μg/lung)	227.8 ± 17.5	318.6 ± 10.2	217.3 ± 9.3

[0036] The inhibition ratio was calculated by the following equation.

[0037] Inhibition ratio

$$= \{[(C - B) - (S - B)] + (C - B)\} \times 100 (\%)$$

S: Hydroxyproline content in bleomycin-induced + S1P-administered group

C: Hydroxyproline content in bleomycin-induced + 0.5% CMC Na- physiological saline-administered group

B: Hydroxyproline content in physiological saline-induced + 0.5% CMC-Na- physiological saline-administered group

[0038] As the above result, S1P suppressed bleomycin-induced the increase of hydroxyproline content by ca. 90%.

Formulation Examples:

Formulation Example 1

[0039] The following components were mixed in the usual way and then subjected to tablet making to thereby obtain 100 tablets containing 50 mg of the active ingredient per tablet.

Sphingosine 1-phosphate	5.0 g
Carboxymethylcellulose calcium (disintegrator)	0.2 g
Magnesium stearate (lubricant)	0.1 g
Microcrystalline cellulose	4.7 g

Formulation Example 2

[0040] The following components were mixed in the usual way, and the solution was sterilized in the usual way, dispensed in 5 ml into ampuls and then freeze-dried in the usual way to thereby obtain 100 ampuls containing 20 mg of the active ingredient per ampul.

Sphingosine 1-phosphate	5.0 g
Mannitol	20 g
Distilled water	500 ml

Claims

1. An anti fibrotic agent, comprising a sphingosine 1-phosphate receptor agonist as an active ingredient.
2. An agent for preventing and/or treating a fibrosis, comprising a sphingosine 1-phosphate receptor agonist as an

EP 1 195 165 A1

active ingredient.

3. The agent for preventing and/or treating a fibrosis according to claim 2, wherein the fibrosis is pulmonary fibrosis, interstitial pneumonia, chronic hepatitis, hepatic cirrhosis, chronic renal failure or renal glomerulosclerosis.

4. An anti fibrotic agent, comprising contains sphingosine 1-phosphate as an active ingredient.

5. An agent for preventing and/or treating a fibrosis, comprising sphingosine 1-phosphate as an active ingredient.

6. The agent for preventing and/or treating a fibrosis according to claim 5, wherein the fibrosis is pulmonary fibrosis, interstitial pneumonia, chronic hepatitis, hepatic cirrhosis, chronic renal failure or renal glomerulosclerosis.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP00/04583

A. CLASSIFICATION OF SUBJECT MATTER Int.Cl. ⁷ A61K45/00, 31/661		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) Int.Cl. ⁷ A61K45/00, 31/661		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Jitsuyo Shinan Koho 1926-1996 Toroku Jitsuyo Shinan Koho 1994-2000 Kokai Jitsuyo Shinan Koho 1971-2000 Jitsuyo Shinan Toroku Koho 1996-2000		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CAS (STN) BIOSIS (STN) REGISTRY (STN) EMBASE (STN) MEDLINE (STN)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
PX	GALLOIS, C. et al, 'Endothelin-1 stimulates sphingosine kinase in human hepatic stellate cells. A novel role for sphingosine-1-P as a mediator of growth inhibition.', Annals of the New York Academy of Sciences, (2000) Vol. 905, pp.311-4	4-6
A	VAN BROCKLYN, James. R. et al, 'Dual actions sphingosine-1-phosphate: extracellular through the Gi-coupled receptor Edg-1 and intracellular to regulate proliferation and survival', The Journal of Cell Biology, (1998) Vol.142, No.1, pp.229-240	4-6
A	MALLAT, Ariane. et al, 'Growth inhibitory properties of endothelin-1 in activated human hepatic stellate cells: a cyclic adenosine monophosphate-mediated pathway', Journal of clinical investigation, (1996) Vol.98, No.12, pp.2771-2778	4-6
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 22 September, 2000 (22.09.00)		Date of mailing of the international search report 10 October, 2000 (10.10.00)
Name and mailing address of the ISA/ Japanese Patent Office Facsimile No.		Authorized officer Telephone No.

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP00/04583

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 1-3
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
Concerning the term "sphingosine-1-phosphate receptor agonist", a person skilled in the art cannot fully understand what substances fall within the category of this agonist. Therefore, it is impossible to perform any meaningful international search but on the substances particularly disclosed in the description.
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (1)) (July 1992)